Clinical Trials at Massachusetts General Hospital

As of July 2026, 630 paid clinical trials are recruiting at Massachusetts General Hospital, located at Faustman Lab at Massachusetts General Hospital, 149 13th St #3602, Boston, MA 02129, phone (617) 726-4084 in Boston, Massachusetts. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

630 clinical trials at Massachusetts General Hospital

·Clear filters·↓ Download CSV

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

for Chronic Graft-versus-host-disease

47 locations incl. Birmingham

Sponsor: Syndax Pharmaceuticals

Sex: All·Age: 2+

Code: NCT04710576·Phase 2·Recruiting

Apply to this trial

Strategy for Improving Stroke Treatment Response

for Ischemic Stroke

52 locations incl. Birmingham

Sponsor: Translational Sciences, Inc.

Sex: All·Age: 18+

Code: NCT05948566·Phase 2·Recruiting

Apply to this trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

41 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06297226·Phase 2·Recruiting

Apply to this trial

Phase 2 Study to Assess the Safety and Efficacy of ANG003

for Exocrine Pancreatic Insufficiency (EPI)

26 locations incl. Long Beach

Sponsor: Anagram Therapeutics, Inc.

Sex: All·Age: 12+

Code: NCT07450547·Phase 2·Recruiting

Apply to this trial

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

for Metastatic Head-and-neck Squamous-cell Carcinoma

28 locations incl. Gilbert

Sponsor: AVEO Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06064877·Phase 3·Recruiting

Apply to this trial

Zenith® Fenestrated+ Clinical Study

for Aortic Aneurysm, Abdominal

32 locations incl. Birmingham

Sponsor: Cook Research Incorporated

Sex: All·Age: 18+

Code: NCT04875429·Recruiting

Apply to this trial

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

for Acute Leukemia

26 locations incl. Duarte

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 2+

Code: NCT04811560·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

Drug: Venetoclax

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting

Apply to this trial

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

for Critical Limb Ischemia

30 locations incl. Gainesville

Sponsor: LimFlow, Inc.

Sex: All·Age: 18 - 95

Code: NCT05313165·Recruiting

Apply to this trial

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

for Myelodysplastic Syndrome

49 locations incl. Duarte

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04227847·Phase 1·Recruiting

Apply to this trial

CCM OPEN HF Registry

for Heart Failure

28 locations incl. Mesa

Sponsor: Impulse Dynamics

Sex: All·Age: 18+

Code: NCT07112924·Recruiting

Apply to this trial

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

for Advanced Melanoma

Drug: Tebentafusp

25 locations incl. Phoenix

Sponsor: Immunocore Ltd

Sex: All·Age: 18+

Code: NCT05549297·Phase 3·Recruiting

Apply to this trial

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

for Persistent Atrial Fibrillation

33 locations incl. Mobile

Sponsor: Boston Scientific Corporation

Sex: All·Age: 18+

Code: NCT06735534·Recruiting

Apply to this trial

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

for Graft-versus-host Disease (GVHD)

Drug: Ruxolitinib

30 locations incl. Palo Alto

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT06615050·Phase 3·Recruiting

Apply to this trial

Global Paradise System US Post Approval Study

for Hypertension

39 locations incl. Sacramento

Sponsor: ReCor Medical, Inc.

Sex: All·Age: 18+

Code: NCT06297291·Recruiting

Apply to this trial

Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System

for Pulmonary Embolism

58 locations incl. Long Beach

Sponsor: Penumbra Inc.

Sex: All·Age: 18+

Code: NCT04798261·Recruiting

Apply to this trial

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

for Myelofibrosis

32 locations incl. Birmingham

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 18+

Code: NCT04176198·Phase 1, Phase 2·Recruiting

Apply to this trial

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

for Complex Congenital Heart Defect

25 locations incl. Little Rock

Sponsor: Edwards Lifesciences

Sex: All·Age: All ages

Code: NCT02744677·Recruiting

Apply to this trial

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

for Atrial Fibrillation (AF)

33 locations incl. Birmingham

Sponsor: Boston Scientific Corporation

Sex: All·Age: 18+

Code: NCT07187115·Recruiting

Apply to this trial

FORWARD CAD IDE Study

for Coronary Arterial Disease (CAD)

28 locations incl. La Jolla

Sponsor: Shockwave Medical, Inc.

Sex: All·Age: 18+

Code: NCT06662500·Recruiting

Apply to this trial

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

for Epithelial Ovarian Cancer

26 locations incl. Phoenix

Sponsor: TORL Biotherapeutics, LLC

Sex: Female·Age: 18+

Code: NCT06690775·Phase 2·Recruiting

Apply to this trial

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

for Aortic Stenosis

Drug: Pelacarsen

38 locations incl. Huntsville

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 50 - 80

Code: NCT05646381·Phase 2·Recruiting

Apply to this trial

CAR-T Long Term Follow Up (LTFU) Study

for Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

44 locations incl. Duarte

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 0 - 100

Code: NCT02445222·Phase 3·Recruiting

Apply to this trial

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

for Parkinson's Disease

28 locations incl. Los Angeles

Sponsor: Boston Scientific Corporation

Sex: All·Age: 18+

Code: NCT02071134·Recruiting

Apply to this trial

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

for Locally Advanced Solid Tumors

Drug: Repotrectinib

49 locations incl. Santa Rosa

Sponsor: Turning Point Therapeutics, Inc.

Sex: All·Age: 12+

Code: NCT03093116·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

for Colorectal Cancer

22 locations incl. Huntsville

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07023289·Phase 2·Recruiting

Apply to this trial

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

for Breast Cancer

14 locations incl. Orlando

Sponsor: Terremoto Biosciences Inc.

Sex: All·Age: 18+

Code: NCT07109726·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

for Acute Myeloid Leukemia

Drug: Venetoclax

24 locations incl. Los Angeles

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06456463·Phase 2·Recruiting

Apply to this trial

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

for Ovarian Neoplasms

20 locations incl. Newport Beach

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07213791·Phase 1·Recruiting

Apply to this trial

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

for Atherosclerosis

Drug: Lepodisiran

17 locations incl. La Jolla

Sponsor: Eli Lilly and Company

Sex: All·Age: 45 - 80

Code: NCT07613294·Phase 3·Recruiting·Listed May 29, 2026

Apply to this trial

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

for Relapsed/Refractory Primary Central Nervous System Lymphoma

Drug: Rituximab

20 locations incl. Phoenix

Sponsor: Ono Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT07104032·Phase 3·Recruiting

Apply to this trial

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

for Glioblastoma (GBM)

18 locations incl. Springdale

Sponsor: Black Diamond Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07326566·Phase 2·Recruiting

Apply to this trial

GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

for Aortic Dissection

18 locations incl. Birmingham

Sponsor: W.L.Gore & Associates

Sex: All·Age: 18+

Code: NCT06827990·Recruiting

Apply to this trial

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

for Advanced Solid Tumor

18 locations incl. Phoenix

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07070232·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

for Amyloid Plaque

13 locations incl. Lady Lake

Sponsor: AC Immune SA

Sex: All·Age: 35 - 85

Code: NCT05462106·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

for Metastatic Solid Tumor

17 locations incl. Santa Monica

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06561685·Phase 1·Recruiting

Apply to this trial

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

for Lymphoma, Non-Hodgkin's

Drug: LY4584180

21 locations incl. Scottsdale

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07226843·Phase 1·Recruiting

Apply to this trial

A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation

for Atrial Fibrillation

11 locations incl. Jonesboro

Sponsor: Biosense Webster, Inc.

Sex: All·Age: 18 - 80

Code: NCT07523750·Recruiting

Apply to this trial

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

for Metastatic Solid Tumor

Drug: LY4052031

18 locations incl. Duarte

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06465069·Phase 1·Recruiting

Apply to this trial

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

for Mesial Temporal Lobe Epilepsy

18 locations incl. Birmingham

Sponsor: UniQure Biopharma B.V.

Sex: All·Age: 18 - 75

Code: NCT06063850·Phase 1, Phase 2·Recruiting

Apply to this trial